Volume : 12, Issue : 12, December- 2025
Title:
NANOTECHNOLOGY USE IN CANCER TREATMENT
Authors :
Ms. Yogita Devendra Dhole , Ms.Komal D. Rathod
Abstract :
Cancer remains one of the leading causes of morbidity and mortality worldwide, and limitations of conventional therapies—including poor tumor selectivity, systemic toxicity, multidrug resistance, and inadequate therapeutic index—continue to drive the search for more precise and effective treatment strategies. Nanotechnology has emerged as a transformative platform for cancer management through the development of nanoscale systems engineered for diagnosis, targeted drug delivery, imaging, and combination therapy. Various nanomaterials such as liposomes, polymeric nanoparticles, dendrimers, metal-based structures, and biomimetic vesicles enable the controlled release of therapeutic agents, enhanced circulation time, improved pharmacokinetics, and preferential tumor accumulation through passive and active targeting mechanisms. In addition to drug delivery, nanotechnology has enabled imaging-guided therapy, photothermal and photodynamic interventions, gene and RNA-based treatments, and immune modulation, offering a multifaceted approach to address tumor growth and metastatic progression. Several nano-enabled therapeutics have reached clinical use or advanced clinical investigation, illustrating their translational potential. Despite these advances, challenges remain, including tumor heterogeneity, variable penetration, immune recognition, long-term toxicity, biomaterial clearance, and manufacturing and regulatory complexities that limit widespread clinical adoption. Current efforts focus on the development of intelligent, stimulus-responsive, patient-specific nanosystem; biodegradable and biomimetic carriers; and computationally guided design pipelines to improve safety and therapeutic outcomes. Overall, nanotechnology provides a powerful framework for enhancing precision oncology. Continued interdisciplinary collaboration and innovation are expected to overcome current barriers, enabling next-generation nanotherapeutic platforms with improved efficacy, safety, and clinical accessibility.
Keywords: Nanotechnology; Cancer therapy; Nanomedicine; Targeted drug delivery; Liposomes; Polymeric nanoparticles; Dendrimers; Biomimetic nanocarriers; Photothermal therapy; Photodynamic therapy; Gene therapy; Immunotherapy; Tumor microenvironment; Clinical translation.
Cite This Article:
Please cite this article in press Yogita Devendra Dhole et al., Nanotechnology Use In Cancer Treatment, Indo Am. J. P. Sci, 2025; 12(12).
Number of Downloads : 10
References:
1. Sung H, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide. CA Cancer J Clin. 2021.
2. Arruebo M, et al. Nanotherapies to overcome cancer drug resistance. Nano Today. 2019.
3. Mitchell MJ, et al. Engineering precision nanoparticles for drug delivery. Nat Rev Cancer. 2021.
4. Shi J, et al. Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer. 2017.
5. Fang J, et al. The EPR effect: Unique features of tumor blood vessels for drug delivery. Adv Drug Deliv Rev. 2020.
6. Blanco E, et al. Principles of nanoparticle design for cancer therapy. Nat Biotechnol. 2015.
7. Goel S, et al. Clinical and preclinical applications of nanotechnology-based cancer therapy. Nat Rev Cancer. 2018.
8. Zhang P, et al. Stimuli-responsive nanocarriers for cancer therapy. Mater Sci Eng C. 2021.
9. Chen H, et al. Theranostic nanoparticles for cancer diagnosis and treatment. Adv Mater. 2021.
10. Wilhelm S, et al. Analysis of nanoparticle delivery to tumors. Nat Rev Mater. 2016.
11. Barenholz Y. Doxil®—The first FDA-approved nanodrug. J Control Release. 2012.
12. Jhaveri AM et al. Polymeric nanoparticles for targeted drug delivery. Adv Drug Deliv Rev. 2020.
13. Abbasi E et al. Dendrimers: Fabrication, characterization and applications. J Drug Deliv Sci Technol. 2017.
14. Riley RS et al. Gold nanoparticles in cancer therapy. Nat Rev Cancer. 2019.
15. Hilger I. In vivo applications of magnetic nanoparticles. J Magn Magn Mater. 2017.
16. Chaudhary S et al. Carbon nanotubes in cancer therapy. Cancer Lett. 2022.
17. Li Z et al. Quantum dots for cancer imaging. Acta Pharm Sin B. 2022.
18. Cabral H et al. Micellar nanomedicines in cancer. Nat Rev Clin Oncol. 2018.
19. Oh JK, Lee DI. Nanogels for cancer therapy. Prog Polym Sci. 2018.
20. Kalluri R, LeBleu V. Exosome-mediated tumor communication. Science. 2020.
21. Manzano M, Vallet-Regí M. Mesoporous silica nanoparticles in cancer. Adv Funct Mater. 2020.
22. Desai N. Albumin-bound paclitaxel. J Clin Oncol. 2009.
23. Hong S et al. Silicate nanoparticles in cancer therapy. Biomaterials. 2021.
24. Mitchell MJ, et al. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2021.
25. Li G, et al. Advances in smart nanotechnology-supported phototherapy and stimuli-responsive systems. Frontiers/PMCID. 2024.
26. Vines JB, et al. Gold nanoparticles for photothermal cancer therapy. Int J Nanomedicine / PMC. 2019.
27. Hou X, et al. Lipid nanoparticles for mRNA delivery. Nat Rev Mater. 2021.
28. Han J, et al. Lipid nanoparticle-based mRNA delivery systems for cancer immunotherapy. Nanoconvergence. 2023.
29. Yao Y, et al. Nanoparticle-based drug delivery in cancer therapy and imaging (theranostics). Frontiers / PMC. 2020.
30. Overchuk M & Zheng G. Photothermal and photodynamic combination therapies: mechanisms and synergies. ACS Nano. 2023.
31. Paunovska K, et al. Drug delivery systems for RNA therapeutics. Nat Rev Genet/Drug Discov. 2022.
32. Cheng X, et al. Advances in nanomaterial-based targeted drug delivery systems. Pharmaceutics / PMC. 2023.
33. Mitchell MJ, et al. Engineering considerations, nano–bio interactions, and translational barriers. Nat Rev Drug Discov. 2021.
34. Barenholz Y. Doxil® clinical overview. J Control Release.
35. Wang-Gillam A et al. Onivyde in pancreatic cancer. Lancet.
36. Von Hoff D et al. Nab-paclitaxel + gemcitabine for pancreatic cancer. N Engl J Med.
37. Ventola CL. Progress of polymeric nanomedicine. P T Journal.
38. Bonvalot S et al. NBTXR3 radiosensitizer in sarcoma. Lancet Oncol.
39. Maier-Hauff et al. NanoTherm in glioblastoma. J Neurooncol.
40. Zhao X et al. Photothermal nanomedicine advances. Nano Today.
41. Hou X et al. Lipid nanoparticles for RNA therapy. Nat Rev Mater.
42. Janib SM et al. Theranostic nanomedicine. Adv Drug Deliv Rev.
43. EL Andaloussi et al. Exosomes in therapy. Nat Rev Drug Discov.
44. Goldberg SL et al. Marqibo in leukemia. Lancet.
45. Anselmo & Mitragotri. Clinical nanomedicines overview. Bioeng Transl Med.
46. Shi J et al. Cancer nanomedicine. Nat Rev Cancer.
47. Hare J et al. Barriers to nanomedicine translation. Nat Nanotechnol.
48. Gawne P.J., et al. New Opportunities and Old Challenges in the Clinical Translation of Nanotheranostics. Frontiers in Nanomedicine / PMC. 2023.
49. Zhang P., et al. Cancer nanomedicine toward clinical translation. Cell Medicine Review. 2023.
50. Fan D., et al. Nanomedicine in cancer therapy: current strategies and future prospects. Signal Transduction and Targeted Therapy. 2023.
51. Nirmala M.J., et al. Cancer nanomedicine: a review of nano-therapeutics and delivery systems. RSC Advances. 2023.
52. Sell M., et al. Application of Nanoparticles in Cancer Treatment: Toxicity and Clearance Considerations. Nanomaterials (MDPI). 2023.
53. Younis M.A., et al. Clinical translation of nanomedicines: challenges, manufacturing and analytical considerations. Pharmaceutics / Reviews. 2022.
54. Hua S., et al. Current trends and challenges in the clinical translation of nanomedicines. Frontiers in Pharmacology. 2018.
55. Review articles on economic, regulatory and adoption challenges in nanomedicine (summarized from multiple sources: Signal Transduction 2023; Nat Rev Drug Discov 2021; Frontiers 2018).
56. Abdullah K.M., et al. Nanomedicine in Cancer Therapeutics: Current Perspectives. Molecular Cancer. 2025.
57. Gawne P.J., et al. New Opportunities and Old Challenges in the Clinical Translation of Nanotheranostics. 2023.
58. Zhang P., et al. Cancer nanomedicine toward clinical translation. 2023.